The Oxford Science Park appoints Jitesh Patel as Development Manager New role enables accelerated delivery of buildings for existing & new occupiers Oxford, UK, January 19 2022 –…
Read More
The Oxford Science Park takes lease on Hayakawa Building, increasing innovation space Flexible accommodation to meet high demand for life sciences facilities Oxford, UK, January 18 2022 – The Oxford…
Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines January 7, 2022 * Collaborative efforts aim to accelerate drug discovery and improve clinical success *…
Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board OXFORD, UK – 6th January 2022 – Joanna Smart, an experienced Director and CEO in the life sciences sector has been…
First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics Oxford, UK – 5th January 2022 – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems…
Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform Agreement includes an upfront payment for four SENSIGHT subscriptions and associated professional services Oxford, U.K. – 24th December…
OrganOx receives FDA approval for metra device OrganOx, a world leader in normothermic machine perfusion (NMP), today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of…
The Oxford Science Park Innovation Award returns as Oxfordshire Business Awards resume Apply now to join previous winners – Oxford Space Systems, Perspectum Diagnostics, Adaptix & Oxford Biomedica Oxford, UK,…
The Oxford Science Park and its occupiers gathered together recently to celebrate successes and progress over recent months – a period in which the importance of science and technology companies in…
Oxford, UK – 10 November 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-inflammation and immuno-oncology, today announces the appointment…
OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins Oxford, United Kingdom – 4 November 2021 – OMass Therapeutics (‘OMass’ or ‘the Company’), a…
Acquisition of ATDBio by Biotage AB to provide platform for further growth Founders look forward to continued focus on customers and innovation Oxford and Southampton, UK, October 20 2021 –…
Scancell expands its R&D capabilities with new facilities at The Oxford Science Park Oxford, UK, 19 October 2021 – Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for…
LANDMARK PAPER HIGHLIGHTS EVOX THERAPEUTICS’ CUTTING EDGE EXOSOME ENGINEERING APPROACH FOR ENHANCED SURFACE DISPLAY OF BIOLOGICS Evox’s engineered exosomes show better efficacy compared to conventional biologics and significantly outperformed other…
Magdalen College & GIC enter Strategic Partnership to accelerate development of The Oxford Science Park Investment initiates transformational construction programme as demand for life sciences & technology space continues…